Omapatrilat (INN,[1] proposed trade name Vanlev) is an experimental antihypertensive agent that was never marketed.[2] It inhibits both neprilysin (neutral endopeptidase, NEP) and angiotensin-converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling.
It was discovered and developed by Bristol-Myers Squibb but failed in clinical trials as a potential treatment for congestive heart failure due to safety concerns about its causing angioedema.[3]
Omapatrilat angioedema was attributed to its dual mechanism of action, inhibiting both angiotensin-converting enzyme (ACE), and neprilysin (neutral endopeptidase), both of these enzymes are responsible for the metabolism of bradykinin which causes vasodilation, angioedema, and airway obstruction.
^"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 40" (PDF). World Health Organization. p. 190. Retrieved 2 March 2017.
Omapatrilat (INN, proposed trade name Vanlev) is an experimental antihypertensive agent that was never marketed. It inhibits both neprilysin (neutral...
amine with succinic anhydride in the presence of pyridine as a base. Omapatrilat McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al...
Chunlin; Kerwin, Linda J.; Block, Alan J.; Pfeffer, Marc A. (25 Jun 2002). "Omapatrilat Reduces Pulse Pressure and Proximal Aortic Stiffness in Patients With...
Chunlin; Kerwin, Linda J.; Block, Alan J.; Pfeffer, Marc A. (25 Jun 2002). "Omapatrilat Reduces Pulse Pressure and Proximal Aortic Stiffness in Patients With...
an enkephalinase inhibitor, used in scientific research. UK-414,495 Omapatrilat (dual inhibitor of NEP and angiotensin-converting enzyme) developed by...
mortality, cardiovascular mortality and hospitalization in LCZ696 arm. Omapatrilat (dual inhibitor of NEP and angiotensin-converting enzyme) developed by...